GlassScriptPhysician profile
Jessica Foley
NPI 1144593328
$5,422.21
in general payments reported to CMS, 2019-2025
26 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $429 · 2023: $1,296 · 2024: $1,605 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,196 · Education: $207 · Consulting Fee: $18.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.39 |
| Education | $207.18 |
| Consulting Fee | $18.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,264.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,173.70 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $795.72 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $501.98 | 2022-2025 | Hyqvia, Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $373.22 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $132.37 | 2022-2025 | |
| Hikma Pharmaceuticals USA | $132.06 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $130.90 | 2021-2025 | |
| Amgen INC. | $103.70 | 2023-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $101.91 | 2025 | Neffy |
| Hospira, INC. | $99.95 | 2022-2024 | |
| Genentech USA, INC. | $98.45 | 2021-2025 | Xolair |
| Kaleo, INC. | $94.18 | 2023-2024 | Auvi-Q |
| Grifols USA, LLC | $69.45 | 2024 | Xembify |
| Csl Behring | $60.40 | 2024-2025 | Haegarda, Hizentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.94 | 2022-2025 | |
| Pharming Healthcare, INC. | $47.63 | 2021 | |
| Azurity Pharmaceuticals, INC. | $27.56 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $25.07 | 2023 | |
| Lilly USA, LLC | $23.97 | 2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.86 | 2023 | |
| Arcutis Biotherapeutics, INC. | $18.24 | 2025 | Zoryve |
| Adma Biomanufacturing LLC | $18.21 | 2023 | |
| Galderma Laboratories, L.P. | $16.69 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.